Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy
- 1 November 2019
- journal article
- research article
- Published by Elsevier in European Journal of Radiology
- Vol. 120, 108701
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Annals of Surgical Oncology, 2013
- Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast CancerAnnals of Surgical Oncology, 2013
- The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewInsights into Imaging, 2013
- Mammographic, US, and MR Imaging Phenotypes of Familial Breast CancerRadiology, 2008
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Annals of Oncology, 2007
- Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2005
- Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center ExperienceJournal of Clinical Oncology, 2004
- Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapyEuropean Radiology, 2004
- MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast CancerAnnals of Surgical Oncology, 2001